Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Consumer Health Profits Boosted By Sales, Division Merger

This article was originally published in The Tan Sheet

Executive Summary

Sales expansion and costs savings from the merger of Novartis' Self-Medication and Nutrition businesses drove Consumer Health division profits in the first six months of 1999, the firm announced Aug. 26.

You may also be interested in...

Novartis Lamisil AT OTC Antifungal Said To Work In One Week

Novartis said its new OTC athlete's foot medication Lamisil AT Cream is the only nonprescription medication that cures athlete's foot with one week of treatment in its announcement that FDA has approved the Rx-to-OTC switch.

Novartis merging OTC, nutrition businesses into new Consumer Health division.

NOVARTIS MERGING SELF-MEDICATION AND NUTRITION UNITS into a new global Consumer Health division and focusing the nutrition segment on health nutrition and functional food, the company announced Aug. 27. Combining the worldwide over-the-counter drug and nutrition businesses "will help us accelerate our pace in shaping and penetrating new market segments such as the emerging field of functional food, whose size is estimated to double to over $20 bil. U.S. dollars in annual sales within four years," Novartis said.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts